Navid Hafez joins The Angeles Clinic as Head of Thoracic Oncology.
Dr. Navid Hafez joins us to lead the Precision Medicine and Thoracic Malignancies Programs at The Angeles Clinic and Research Institute from the Smilow Cancer Center at Yale. During his time at Yale, Dr. Hafez contributed to the growth and success of the Early Therapeutics Division of the Section of Medical Oncology with a focus on novel drug development in Immunotherapy and Targeted therapeutics. His primary focus is the clinical care for patients with thoracic malignancies through his expertise. His resume is one of dedication and service of benefiting patients through early phase clinical trials of novel cancer therapeutics. At Yale he was recognized as NCI-ECTCN investigator and the national and/or site-specific Principal Investigator of several NCI-CTEP-ECTCN national studies.
The breakthroughs we make here at TACRI will improve outcomes for patients off all backgrounds and nationalities here in the US and around the world – Navid Hafez, M.D.
Dr. Hafez holds a Masters in Public Health developed through a deep interest in health equity and inclusion across the health care system. He holds the experience needed to overcome the intricacies of health disparities and health services, committed to expanding access to cutting edge therapies to all populations. As the Community, Outreach, and Equity liaison for the Developmental Therapeutics Division of the Yale Cancer Center. This work was elevated through his award of the Robert Winn Diversity in Clinical Trials Career Development Award (Winn CDA) to support increased diversity in clinical trials. We share the same goal: Enhanced development of cancer therapeutics for under represented populations.
Expertise: Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), Mesothelioma, Immune Toxicity, Precision Medicine, Biomarkers, Tumor Board, Biorespository-Biobank.